Drug Profile

LNTH 2404

Alternative Names: LNTH-2404; RAD-206

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Radiopharm Theranostics
Developer Lantheus Holdings
Class Antineoplastics; Immunoconjugates; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2025 Preclinical trials in Solid tumours in USA (unspecified route) prior to January 2025 (Lantheus Holdings, Pipeline, January 2025)
21 Jun 2024 Lantheus Holding in-licenses RAD 206 from Radiopharm Thranostics
17 Jun 2022 Preclinical trials in Breast cancer in Australia (Lantheus Pipeline, January 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com